New hope for PNH patients with stubborn anemia

NCT ID NCT07187401

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study tests an experimental drug called ALN-CFB in people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cells despite standard treatment. The goal is to see if adding ALN-CFB is safe and can improve anemia. About 24 participants will receive either the drug or a placebo, and researchers will monitor side effects and blood levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, PNH are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hemoglobinuria, Paroxysmal paroxysmal nocturnal hemoglobinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, PNH PERSISTENT ANEMIA

Contacts and locations

Locations

Kings College Hospital NHS Foundation Trust
RECRUITING

London, SE5 9RS, United Kingdom
Samsung Medical Center
RECRUITING

Seoul, 6351, South Korea
Seoul National University Hospital
RECRUITING

Seoul, 3080, South Korea
Severance Hospital
RECRUITING

Seoul, 3722, South Korea
St. James's University Hospital
RECRUITING

Leeds, West Yorkshire, LS97TF, United Kingdom
St. Vincent Hospital - The Catholic University of Korea
RECRUITING

Suwon, Gyeonggi-do, 16247, South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital
RECRUITING

Seoul, 06591, South Korea
Toronto General Hospital
RECRUITING

Toronto, Ontario, M5G 2C4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.